Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis
暂无分享,去创建一个
Feng-Chun Yang | Xianlin Yang | K. Mohammad | T. Guise | Zhaomin Li | Shi Chen | Mingjiang Xu | Steven D. Rhodes | Hao Yang | Ruizhi Dong | Keshav Menon | Yongzheng He | Zhaomin Li | Karl W. Staser | Li Jiang | Xiaohua Wu | Xianghong Peng | Khalid S. Mohammad | Theresa A. Guise | Mingjiang Xu | Steven D Rhodes | Feng-Chun Yang | Shi Chen | X. Peng | K. Staser | Yongzheng He | Xianlin Yang | K. Menon | Li Jiang | Xiaohua Wu | Hao Yang | Ruizhi Dong | Keshav Menon
[1] M. Klemsz,et al. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. , 1993, Blood.
[2] M. Klemsz,et al. Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. , 1993, Science.
[3] N. Eskiyurt,et al. Bone mineral density in children with neurofibromatosis 1 , 2007, Acta paediatrica.
[4] Menggang Yu,et al. Ras Dependent Paracrine Secretion of Osteopontin by Nf1+/− Osteoblasts Promote Osteoclast Activation in a Neurofibromatosis Type I Murine Model , 2009, Pediatric Research.
[5] C. Der,et al. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Cassady,et al. Transgenic mice that express Cre recombinase in osteoclasts , 2004, Genesis.
[7] E. Flory,et al. PKCδ‐Induced PU.1 Phosphorylation Promotes Hematopoietic Stem Cell Differentiation to Dendritic Cells , 2011, Stem cells.
[8] T. Kuorilehto,et al. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. , 2010, Bone.
[9] E. Sitnicka,et al. Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow , 2012, The Journal of experimental medicine.
[10] S. Shapiro,et al. Osteoclasts are important for bone angiogenesis. , 2010, Blood.
[11] J. Carey,et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. , 2007, The Journal of pediatrics.
[12] A. Robling,et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. , 2007, Human molecular genetics.
[13] S. Teitelbaum,et al. Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.
[14] D. Largaespada,et al. Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.
[15] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[16] Q. Guo,et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? , 2013, Journal of Translational Medicine.
[17] K. Mohammad,et al. Hyperactive Transforming Growth Factor‐β1 Signaling Potentiates Skeletal Defects in a Neurofibromatosis Type 1 Mouse Model , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] J. Tolar,et al. Osteopetrosis. , 2004, The New England journal of medicine.
[19] M. Frech,et al. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.
[20] E. Jokinen,et al. A controlled register‐based study of 460 neurofibromatosis 1 patients: Increased fracture risk in children and adults over 41 years of age , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] D. Tenen,et al. Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Miller,et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .
[23] J. Marth,et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. , 2001, Genes & development.
[24] R. Bloigu,et al. Decreased bone mineral density and content in neurofibromatosis type 1: Lowest local values are located in the load-carrying parts of the body , 2005, Osteoporosis International.
[25] J.,et al. The New England Journal of Medicine , 2012 .
[26] J. Devente,et al. Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. , 1996, Blood.
[27] A. Paller. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis , 1993 .
[28] V. Riccardi,et al. Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1993 .
[29] E. Everett,et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. , 2005, Bone.
[30] J. Carey,et al. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1 , 2011, American journal of medical genetics. Part A.
[31] D. Ron,et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. , 2006, Cell metabolism.
[32] D. Kufe,et al. Expression of the c-fms proto-oncogene during human monocytic differentiation , 1985, Nature.
[33] A. Robling,et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. , 2006, The Journal of clinical investigation.
[34] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] T. Jacks,et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells , 1996, Nature Genetics.
[36] J. Dubousset,et al. Decreased Bone Mineral Density in Neurofibromatosis-1 Patients with Spinal Deformities , 2001, Osteoporosis International.
[37] S. Peltonen,et al. Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. , 2012, Bone.
[38] S. Marks,et al. Congenitally osteopetrotic (oplop) mice are not cured by transplants of spleen or bone marrow cells from normal littermates. , 1984, Metabolic bone disease & related research.
[39] F. Moreau-Gachelin,et al. Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides. , 1994, Oncogene.
[40] G. Hutchins,et al. Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.
[41] A. Robling,et al. Erratum: Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1 (Human Molecular Genetics (2008) vol. 17(7) (936-948) 10.1093/hmg/ddm366) , 2008 .
[42] W. Reith,et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.
[43] S. Mckercher,et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.
[44] Matthew J. Silva,et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.
[45] M. Rouleau,et al. Roles of osteoclasts in the control of medullary hematopoietic niches. , 2014, Archives of biochemistry and biophysics.
[46] C. Cowell,et al. Decreased Bone Mineral Density in Neurofibromatosis Type 1: Results From a Pediatric Cohort , 2007, Journal of pediatric orthopedics.
[47] S. Peltonen,et al. Phenotypic characterization of transgenic mice harboring Nf1+/− or Nf1−/− osteoclasts in otherwise Nf1+/+ background , 2012, Journal of cellular biochemistry.
[48] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[49] R. Friedrich,et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1) , 2008, Journal of Medical Genetics.
[50] M. Frech,et al. Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.
[51] J. Lloyd,et al. Osteopetrosis , 1972 .
[52] S. Nishikawa,et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.
[53] G D Roodman,et al. Cell biology of the osteoclast. , 1999, Experimental hematology.
[54] G. Bollag,et al. Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1−/− Cells* , 2001, The Journal of Biological Chemistry.
[55] A. Robling,et al. The Haploinsufficient Hematopoietic Microenvironment Is Critical to the Pathological Fracture Repair in Murine Models of Neurofibromatosis Type 1 , 2011, PloS one.
[56] E. Scott,et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.
[57] S. Peltonen,et al. Follow-Up of Six Patients with Neurofibromatosis 1-Related Osteoporosis Treated with Alendronate for 23 Months , 2014, Calcified Tissue International.
[58] S. Störkel,et al. Decreased bone mineral density in patients with neurofibromatosis 1 , 2005, Osteoporosis International.